IL15 and neoplasm: Furthermore, we obtained similar results in the more rapidly progressing B16F10-claudin 18.2 melanoma model by adopting the same treatment regimen (Figures 3G, H, mean tumor volume on Day 15 post CAR-T-cell injection: 525.5 vs. 1095.3 mm3, p < 0.0001; Figure 3I, TGI: 79.3% vs. 57.0%, n = 5 for H9 CAR-IL15 vs. H9 CAR).